Literature DB >> 12798629

Comparison of PorA VR types and porA promoter sequence from Neisseria meningitidis B isolated from non-immunised children and vaccine failures immunised with a serogroup B outer membrane protein vaccine.

Maria Cecília O Gorla1, Ana Paula S Lemos, Claudio T Sacchi, José Cássio de Moraes, Lucimar G Milagres.   

Abstract

PorA protein is an important component of group B meningococcal protein-based vaccines. The goals of this study were: (i) to classify the non-serosubtypable strains recovered from vaccine failures and controls by porA variable region (VR) type; (ii) to investigate if point mutations of VRs of the porA gene are present in P1.19,15 strains recovered from vaccine failures and controls; (iii) to investigate if nucleotide sequence variation in the promoter region of porA gene is related to low expression of PorA protein. VR type P1.19,15 predominated in younger vaccine failures (3-47 months) compared to older failures (48-83 months). No changes in VRs of porA were observed in 46 P1.19,15 strains studied. A promoter spacer of 16bp and 10 guanidine residues in the polymeric G tract was detected in five of six strains with weak PorA expression. Overall, this study indicated that lack of antibody response was probably the major cause of low vaccine efficacy in young children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12798629     DOI: 10.1016/s0264-410x(03)00166-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  First report of capsule replacement among electrophoretic type 37 Neisseria meningitidis strains in Italy.

Authors:  Paola Stefanelli; Cecilia Fazio; Arianna Neri; Tonino Sofia; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

2.  The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.

Authors:  D R Martin; N Ruijne; L McCallum; J O'Hallahan; P Oster
Journal:  Clin Vaccine Immunol       Date:  2006-04

3.  Stability of PorA during a meningococcal disease epidemic.

Authors:  A F Devoy; K H Dyet; D R Martin
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

4.  Phase variation of PorA, a major outer membrane protein, mediates escape of bactericidal antibodies by Neisseria meningitidis.

Authors:  Isfahan Tauseef; Youssif M Ali; Christopher D Bayliss
Journal:  Infect Immun       Date:  2013-02-12       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.